Literature DB >> 26031761

Consistent copy number changes and recurrent PRKAR1A mutations distinguish Melanotic Schwannomas from Melanomas: SNP-array and next generation sequencing analysis.

Lu Wang1, Ahmet Zehir1, Justyna Sadowska1, Nengyi Zhou1, Marc Rosenblum1, Klaus Busam1, Narasimhan Agaram1, William Travis1, Maria Arcila1, Snjezana Dogan1, Michael F Berger1,2, Donavan T Cheng1, Marc Ladanyi1,2, Khedoudja Nafa1, Meera Hameed1.   

Abstract

Melanotic Schwannomas (MS) are rare tumors that share histological features with melanocytic tumors and schwannomas. However, their genetics are poorly understood. To elucidate the genetic characteristics of MS, we performed genome-wide studies in a series of cases. Twelve MS cases were available for the study. Genomic DNAs extracted from formalin-fixed paraffin embedded tumor tissues were subjected to copy number (CN) and allelic imbalance (AI) analysis by Single Nucleotide Polymorphism (SNP)-array and screened for mutations in coding exons of 341 key cancer-associated genes using a hybrid capture-based next-generation sequencing (NGS) assay. Sanger sequencing was used to further verify recurrent mutations detected by NGS study. SNP-array analysis revealed remarkably stereotypic chromosomal abnormalities in MS. Hypodiploidy was common, typically involving monosomies of chromosomes 1, 2, and 17. All 12 samples showed mutations in PRKAR1A gene, including 2 cases with 2 mutations each. The 14 mutations were scattered across PRKAR1A, and most were inactivating mutations. AI on 17q, presenting as loss of heterozygosity with or without CN losses, combined with a PRKAR1A mutation was observed in 9/12 MS cases. The remaining 3 cases included the two samples harboring two mutations in PRKAR1A. MS exhibits a stereotypic pattern of chromosomal losses. In contrast, melanomas are typically characterized by the presence of multiple CN aberrations, without demonstrable differences in the frequency of losses and gains. Inactivation of both alleles of PRKAR1A by "two hits" observed in almost all cases underscores the central role of PRKAR1A in the pathogenesis of this neoplasm.
© 2015 Wiley Periodicals, Inc. © 2015 Wiley Periodicals, Inc.

Entities:  

Year:  2015        PMID: 26031761      PMCID: PMC6446921          DOI: 10.1002/gcc.22254

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  10 in total

1.  Myxoid fibroadenomas differ from conventional fibroadenomas: a hypothesis-generating study.

Authors:  John R Lozada; Kathleen A Burke; Aoife Maguire; Fresia Pareja; Raymond S Lim; Jisun Kim; Rodrigo Gularte-Merida; Melissa P Murray; Edi Brogi; Britta Weigelt; Jorge S Reis-Filho; Felipe C Geyer
Journal:  Histopathology       Date:  2017-07-05       Impact factor: 5.087

Review 2.  Genetic counseling and tumor predisposition in neuro-oncology practice.

Authors:  Erin M Dunbar; Amanda Eppolito; John W Henson
Journal:  Neurooncol Pract       Date:  2015-10-31

Review 3.  Practical Approach to Histological Diagnosis of Peripheral Nerve Sheath Tumors: An Update.

Authors:  Gaetano Magro; Giuseppe Broggi; Giuseppe Angelico; Lidia Puzzo; Giada Maria Vecchio; Valentina Virzì; Lucia Salvatorelli; Martino Ruggieri
Journal:  Diagnostics (Basel)       Date:  2022-06-14

4.  EANO guideline on the diagnosis and treatment of vestibular schwannoma.

Authors:  Roland Goldbrunner; Michael Weller; Jean Regis; Morten Lund-Johansen; Pantelis Stavrinou; David Reuss; D Gareth Evans; Florence Lefranc; Kita Sallabanda; Andrea Falini; Patrick Axon; Olivier Sterkers; Laura Fariselli; Wolfgang Wick; Joerg-Christian Tonn
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300

Review 5.  Diagnostic Pathology of Tumors of Peripheral Nerve.

Authors:  Sarra M Belakhoua; Fausto J Rodriguez
Journal:  Neurosurgery       Date:  2021-02-16       Impact factor: 4.654

6.  Novel response to neoadjuvant anti-PD1 therapy for a patient with retrocaval melanotic schwannoma.

Authors:  Charles C Vining; Phillip J Hsu; Aaron Miller; Daniel J Olson; Thomas F Gajewski; Peter Pytel; Bruce S Bauer; Michael J Millis; Kevin K Roggin
Journal:  Melanoma Res       Date:  2021-02-01       Impact factor: 3.199

7.  Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray.

Authors:  Hui Chen; Rajesh R Singh; Xinyan Lu; Lei Huo; Hui Yao; Kenneth Aldape; Ronald Abraham; Shumaila Virani; Meenakshi Mehrotra; Bal Mukund Mishra; Alex Bousamra; Constance Albarracin; Yun Wu; Sinchita Roy-Chowdhuri; Rashmi Kanagal-Shamanna; Mark J Routbort; L Jeffrey Medeiros; Keyur P Patel; Russell Broaddus; Aysegul Sahin; Rajyalakshmi Luthra
Journal:  Oncotarget       Date:  2017-02-14

Review 8.  Diagnostic Immunohistochemistry of Soft Tissue and Bone Tumors: An Update on Biomarkers That Correlate with Molecular Alterations.

Authors:  William J Anderson; Vickie Y Jo
Journal:  Diagnostics (Basel)       Date:  2021-04-12

Review 9.  A para-aortic malignant melanotic nerve sheath tumor mimicking a gastrointestinal stromal tumor: a rare case report and review of literature.

Authors:  Kuan-Yu Lin; Lujen Chen; Chih-Jung Chen; Kun-Yuan Chiu; Siu-Wan Hung; Sheng-Chun Hung; Cheng-Kuang Yang
Journal:  BMC Surg       Date:  2022-07-28       Impact factor: 2.030

10.  Can Discord Domain-Containing Receptor 2 Mutation Act as a Disease Modifier for PRKAR1A Associated Melanotic Schwannoma?

Authors:  Erica M Roman Hernandez; Sri Laxmi Valasareddi; Jarrod Adkison; Henna Awan; Krishnamohan R Basarakodu; Arash Velayati
Journal:  Case Rep Oncol       Date:  2021-06-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.